INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/41372

A. CLASSIFICATION OF SUBJECT MATTER		
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12P 12/08, 21/08; A61K 39/395		
US CL : 530/387.3; 435/326; 424/133.1		
According to International Patent Classification (IPC) or to be	oth national classification and IDC	
B. FIELDS SEARCHED	on hadolal classification and IPC	
Minimum documentation seembed (alexaification mater 5-11		
Minimum documentation searched (classification system follow U.S.: 530/387.3; 435/326; 424/133.1	wed by classification symbols)	
0.0 0.007.0, 425/320, 424/155.1		
Documentation searched other than minimum documentation to	o the extent that such documents are include	d in the fields searched
Clastronia data hara annulu data da da data da da da da data da		
Electronic data base consulted during the international search (Please See Continuation Sheet	name of data base and, where practicable,	search terms used)
rease see Continuation sheet		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category * Citation of document, with indication, where	e appropriate, of the relevant passages	Relevant to claim No.
X / Lu, D. Complete Inhibition of Vascular Endoth	elial Growth Factor (VEGF) Activities	1-5, and 23-42
with a Bifunctional Diabody Directed against Bo	th VEGF Kinase Recentors, frus-like	1-5, and 25-42
Tyrosine Kinase Receptor and Kinase Insert Don	nain-containing Receptor Cancer	
Research October 2001, Vol 61. pages 7002-700	8, especially page 7005, Table 1, page	
7004, and Figure 1.		·
Y / Lu. D. Acquired Antagonistic Activity of a Bisp	ecific Diabody Directed Against Two	1-4, 24-28, 30-34, and
Different Epitopes on Vascular Endothelial Grov	vth Factor Receptor 2 J. Immunol.	36-42
Methods November 1999, Vol 230. No. 1-2, pa	ges 159-71, especially abstract.	
i		
	j	
Further documents are listed in the continuation of Box C.	See patent family annex.	
* Special categories of cited documents:	"T" later document published after the intern	national filing data as a signifu
"A" document defining the general state of the art which is not considered to be	date and not in conflict with the applicat	tion but cited to understand the
of particular relevance	principle or theory underlying the invent	tion.
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the cl	aimed invention cannot be
The state of the s	considered novel or cannot be considere when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as		
specified)	"Y" document of particular relevance; the cle considered to involve an inventive step v	aimed invention cannot be
O" document referring to an oral disclosure, use, exhibition or other means	combined with one or more other such d	ocuments, such combination
to all oral abolicants, and, extraction of other means	being obvious to a person skilled in the a	art
P* document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent far	nily
Date of the actual completion of the international search	Date of mailing of the international searc	h report
30 April 2003 (30.04.2003)	Date of mailing of the international search report	
Name and mailing address of the ISA/US	Authorized officer	
Commissioner of Patents and Trademarks	17 17 . 1	t . \wedge .
Box PCT Washington, D.C. 20231	Phuong Huynh	in Clian
Facsimile No. (703)305-3230	Telephone No. (703) 308-0196	- Concernance
rm PCT/ISA/210 (second sheet) (July 1998)		

INTERNATIONAL SEARCH REPORT	FC1/0302/413/2	
		4
		•
·		
	Y	
Continuation of B. FIELDS SEARCHED Item 3:	·	
MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS on STN Chimeric VEGF receptor antibody, KDR, Flt-1, Flt-4, diabody, method making	antibodies	
•		
•		
		ĺ
`		I
		- 1
		- 1

Form PCT/ISA/210 (second sheet) (July 1998)